Implant for Walking After Stroke

Sponsor
MetroHealth Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05740540
Collaborator
Case Western Reserve University (Other), Louis Stokes VA Medical Center (U.S. Fed), Cleveland State University (Other)
6
2
1
52
3
0.1

Study Details

Study Description

Brief Summary

This is a device study that will evaluate the effect of an implanted stimulator on improving walking in stroke survivors. There are two phases in the study: 1) Screening - this phase determines if the individual is a good candidate to receive an implanted system, 2) Implantation, controller development, and evaluation - this phase includes installing the device and setting the individual up for home use, creating advanced controllers for walking and evaluating the effect of the device over several months.

Condition or Disease Intervention/Treatment Phase
  • Device: IRS-8
  • Device: IST 12 & IST 16
N/A

Detailed Description

The purpose of this study is to evaluate the effects of neural stimulation for improving walking after stroke. Participants will undergo surgery to implant a stimulator and electrodes to activate muscles used during walking. The device delivers electrical pulses to the nerves causing the muscles to contract to perform functional movements. The system coordinates assistance based on external sensors. After receiving the implanted device, participants undergo training to use the device to assist walking. Evaluations are completed prior to surgery as well after training and at later follow up sessions.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
6 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Customizable Cooperative Multi-joint Control to Enhance Walking Mobility After Stroke
Actual Study Start Date :
Nov 30, 2022
Anticipated Primary Completion Date :
Mar 31, 2027
Anticipated Study Completion Date :
Mar 31, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Implantation, controller development, and evaluation

This phase includes installing the device and setting the individual up for home use, creating advanced controllers for walking and evaluating the effect of the device over several months.

Device: IRS-8
Implanted Receiver Stimulator (IRS) delivering 8 channels of stimulation. Appropriate for muscle-based (intramuscular or epimysial) electrodes only

Device: IST 12 & IST 16
Implantable Stimulator Telemeter (IST) that provides 12 independent channels of stimulation with the option of 2 channels of bipolar myoelectric signal recording, or 16 independent stimulus channels. Suitable for muscle-based or nerve cuff electrodes such as the CWRU Spiral, Flat Interface Nerve Electrode (FINE) or Composite-Flat Interface Nerve Electrode (C-FINE).

Outcome Measures

Primary Outcome Measures

  1. Difference in Gait speed [baseline, ~18 weeks post implant, ~44 week post implant]

    The 10mWT is used to assess walking speed in meters/second (m/s) over a short distance. Gait speed is how we're evaluating whether the advanced controller works better than a simple generic triggering approach.

Secondary Outcome Measures

  1. Difference in Usability Rating Scale (URS) [baseline, ~18 weeks post implant, ~44-week post implant]

    participants will rate the task on a seven-point scale from "very easy" (3) to "very difficult" (-3). Difficulty will be assessed after the 10 m walk test

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • At least 6-months post stroke

  • Age 21 to 75 years old

  • Able to ambulate, but does not require the assistance of more than one person

  • Walk slower than 0.8m/s during a 10m walk test

  • Lower extremity Fugl-Meyer Motor Assessment (FMA) <= 20

  • Reduced peak hip, knee and/or ankle range of motion during stance or swing phases

  • Modified Ashworth Scale (MAS) <= 2 at the above joints during passive flexion and extension

  • Innervated and excitable lower extremity and trunk musculature

  • Appropriate body habitus (height and weight within acceptable limits as determined by study physician)

  • Adequate social support and stability

  • Willingness to comply with follow-up procedures

  • Neurologically stable as determined by a physician

Exclusion Criteria:
  • Non-English speaking

  • Significant range of motion limitations (lacking hip extension, etc.)

  • History of spontaneous fractures or other evidence of excessively low bone density

  • Acute orthopedic problems (severe scoliosis, joint dislocations, etc.)

  • Medical complications (cardiac abnormalities, skin breakdowns, uncontrolled seizures, immunological/pulmonary/renal/circulatory compromise, additional neurologic conditions etc.)

  • Cardiovascular or pulmonary disease

  • Uncontrolled diabetes or hypertension

  • Presence of a demand pacemaker or cardiac defibrillator

  • Pregnancy

  • Complications of stroke that result in an increased risk of falls (apraxia, uncompensated hemineglect, hemianopsia etc.)

  • Significant history of repeated falls

  • Severely impaired cognition and communication

  • Any other medical or psychological condition that would be a contraindication

Contacts and Locations

Locations

Site City State Country Postal Code
1 Louis Stokes Cleveland Veterans Affairs Medical Center Cleveland Ohio United States 44106
2 MetroHealth Medical Center Cleveland Ohio United States 44109

Sponsors and Collaborators

  • MetroHealth Medical Center
  • Case Western Reserve University
  • Louis Stokes VA Medical Center
  • Cleveland State University

Investigators

  • Principal Investigator: Nathan Makowski, PhD, The MetroHealth System

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nathaniel Makowski, Assistant Professor, MetroHealth Medical Center
ClinicalTrials.gov Identifier:
NCT05740540
Other Study ID Numbers:
  • StudyID00000125
First Posted:
Feb 23, 2023
Last Update Posted:
Feb 23, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2023